JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 22, 2006; DOI: 10.1124/jpet.106.104901

0022-3565/06/3183-1027-1032$20.00
JPET 318:1027-1032, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.104901v1
318/3/1027    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pridjian, G.
Right arrow Articles by Puschett, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pridjian, G.
Right arrow Articles by Puschett, J. B.

CARDIOVASCULAR

Beneficial Effects of Metolazone in a Rat Model of Preeclampsia

Gabriella Pridjian, Candice Pridjian, Svitlana Danchuk, Monica Ianosi-Irimie, Hop V. Vu, and Jules B. Puschett

Departments of Obstetrics and Gynecology (G.P.) and Medicine (C.P., S.D., M.I.-I., H.V.V., J.B.P.), Section of Nephrology, Tulane University School of Medicine, New Orleans, Louisiana

Preeclampsia is a disorder that continues to exact a significant toll with respect to maternal morbidity and mortality as well as fetal wastage. Furthermore, the treatment of this disorder has not changed significantly in 50 years and is unsatisfactory. The use of diuretics in this syndrome is controversial because there is a concern related to potential baleful effects of volume contraction leading to a possible further decrement in the perfusion of the maternal-fetal unit. Metolazone is a diuretic/antihypertensive agent, which has a therapeutic effect on blood pressure (BP) in human essential hypertension without causing a natriuresis. We administered the drug in nondiuretic doses in a rat model of preeclampsia previously developed in this laboratory. The drug reduced BP without an accompanying natriuresis. Although there was a trend toward an improvement in intrauterine growth restriction, as determined by litter size and the number of pups demonstrating malformations, the values did not reach statistical significance. We conclude that metolazone, in low dosage, is an effective antihypertensive in this rat model. These studies have implications for the treatment of the human disorder.

Received March 29, 2006; accepted May 18, 2006.

Address correspondence to: Dr. Gabriella Pridjian, Department of Obstetrics and Gynecology, SL-11, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA 70112-2699. E-mail: gabriella.pridjian{at}tulane.edu






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.